India lets Actos back onto market, with warnings; Regeneron's Eylea sales slow; GSK files for new Cervarix approval;

@FiercePharma: Looking for a sales job? Lundbeck to hire > 200 to market antidepressant Brintellix, in prep for FDA nod. More | Follow @FiercePharma

@CarlyHFierce: In Vivus earnings, not a lot of revenue, but analysts seem optimistic about Zook's plans for Qsymia. Release | Follow @CarlyHFierce

> India has reversed itself on the diabetes drug Actos, allowing the treatment and its generics back onto the market, provided manufacturers add bladder-cancer warnings to its labeling. Report

> Sales of Regeneron's ($REGN) fast-growing eye drug Eylea slowed in the second quarter as existing patients moved to less-frequent dosing. Report

> India's Ranbaxy Laboratories posted an unexpected loss of 5.24 billion rupees, or about $85.28 million, on foreign exchange losses and goodwill charges; sales dropped by 17.8% as well. Report

> GlaxoSmithKline ($GSK) asked European regulators to approve a new, two-dose schedule for its human papillomavirus vaccine Cervarix; the currently approved schedule requires three doses. Report

> In a draft assessment, German pricing authorities determined that Almirall's irritable bowel syndrome treatment Constella offered no added benefit compared with existing treatments. Report

> German drugmaker Stada said its executive committee member in charge of production, Axel Mueller, had resigned for personal reasons on "most agreeable terms." Report

> Indian pricing regulators were to meet today with drugmakers about the implementation of new price controls. Report

Medical Device News

@FierceMedDev: Navidea's losses widen as it waits for Lymphoseek to catch on. Article | Follow @FierceMedDev

@DamianFierce: Israel's Given Imaging had a record Q2 and believes better things are on the horizon. Report | Follow @DamianFierce

> Gene By Gene grabs GE-backed diagnostics startup. More

> Roche Dx cuts more diabetes jobs amid faltering sales. Report

> Medtronic implant could point to future of Parkinson's treatment. Story

Biotech News

@FierceBiotech: Report: Seattle biotech VLST unloads assets and shuts doors. More | Follow @FierceBiotech

@JohnCFierce: Acceleron pitches $75M IPO as Celgene pushes partnership through PhII. News | Follow @JohnCFierce

@RyanMFierce: Now that "microbiome" means something to people... NuMe Health changes name to MicroBiome Therapeutics. Release | Follow @RyanMFierce

@EmilyMFierce: The Smithsonian plans to create a huge bank of genetic samples to enable large-scale genome sequencing. More | Follow @EmilyMFierce

> Vaxart garners $20M VC round for vaccine pills. Item

> Report: Determined Amgen sweetens its bid for Onyx Pharma. Story

> FDA experts give Bayer's riociguat unanimous backing for lung disease. Article

Biomarkers News

> Biomarker IDs cancer patients most likely to respond to EGFR inhibitors. Item

> NIH pushes for biomarker research to catch up with needs of kids. Story

> Are cancer biomarker tests grossly underused? More

> Elevated carbon monoxide levels in breath can point to infection. Story

> Broad, Dana-Farber license lung cancer biomarker IP to MolecularMD. Article

> Altered enzyme indicates Alzheimer's-like dementia. Item

Drug Delivery News

@MichaelGFierce: 'Soft robotic' hydrogel arms show drug delivering capability. More | Follow @MichaelGFierce

> UCSD surgeons deliver cancer drugs to brain with ClearPoint MRI tech. Story

> 3M sells dry powder inhaler rights to Adamis. News

> Next-gen Alzheimer's drug targets brain enzyme. Story

> Ocular Therapeutix nets FDA panel meeting for eye surgery hydrogel. Item

> Halozyme regrouping after ViroPharma trial flop. Article

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.